Fed. Circ. Gives Mylan 2nd Chance To Ax AstraZeneca IP
A split Federal Circuit panel on Wednesday gave Mylan another chance to try to show that its planned generic of AstraZeneca's inhaler asthma treatment Symbicort doesn't infringe a trio of patents...To view the full article, register now.
Already a subscriber? Click here to view full article